We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Michael A. Kalwat is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2013 — 2016 |
Kalwat, Michael Andrew |
F32Activity Code Description: To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. |
Role of Isoxazole Compounds in Beta Cell Differentiation and Function @ Ut Southwestern Medical Center
DESCRIPTION (provided by applicant): Blood glucose homeostasis is maintained by a balance between insulin secretion from pancreatic islet beta cells in response to elevated glucose and insulin-stimulated glucose uptake in peripheral tissues. Defects in both of these processes cause type 2 diabetes, a disease of elevated blood glucose that eventually leads to comorbidities like blindness and increased risk for cardiovascular disease. Recent genome-wide association studies have indicated that many genes linked to type 2 diabetes have roles in the pancreatic islet beta cell. In late-stage type 2 diabetes, both beta cell function and beta cell mass are reduced. Thus, the long-term goal of this research is to understand the molecular mechanisms that regulate beta cell identity and function to advance therapeutic strategies for diabetes. Our findings show that 3, 5- substituted isoxazole compounds (ISX) exert a pro-differentiation effect in beta cells, leading to increased expression of transcription factors required for beta cell function. Three specific aims are proposed to test the hypothesis that ISX enhances beta cell differentiation and function: 1) Determine how ISX regulates histone acetyltransferases in the beta cell, 2) Identify direct targets of ISX, and 3) Determine therapeuti effectiveness of ISX in models of diabetes. The proposed research will involve cell-based and in vitro biochemical assays to determine the direct effects of ISX on candidate target proteins. An unbiased protease resistance assay will be used to validate previously identified ISX targets and discover new targets. Studies will be carried out in mice and the clonal mouse beta cell line MIN6 and validated in human islets whenever possible. It is anticipated that the target(s) of ISX in beta cells will be identified, a mechanism of action will be found, and efficacy of ISX in diabetic mice will be determined. This research will pave the way for future studies on ISX compounds for the treatment of diabetes in humans. Given that more than 8% of the United States population has diabetes, this research is particularly relevant and timely. The proposed studies on ISX hold a wealth of potential for enhancing human islet function ex vivo for transplantation and in vivo for diabetes therapy.
|
0.964 |